S
Susan M. Domchek
Researcher at University of Pennsylvania
Publications - 501
Citations - 37655
Susan M. Domchek is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 83, co-authored 439 publications receiving 30495 citations. Previous affiliations of Susan M. Domchek include Brigham and Women's Hospital & Cancer Council Victoria.
Papers
More filters
Journal ArticleDOI
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007
Gordon F. Schwartz,Kevin S. Hughes,Henry T. Lynch,Carol J. Fabian,Ian S. Fentiman,Mark E. Robson,Susan M. Domchek,Lynn C. Hartmann,Roland Holland,David J. Winchester,Benjamin O. Anderson,Banu Arun,Harry Bartelink,Philip S. Bernard,Bernardo Bonanni,Blake Cady,Krishna B. Clough,Stephen A. Feig,Sylvia H. Heywang-Köbrunner,Anthony Howell,Claudine Isaacs,Daniel B. Kopans,Robert E. Mansel,Shahla Masood,Juan P. Palazzo,Peter I. Pressman,Lawrence J. Solin,Michael Untch +27 more
TL;DR: Four categories of risk were outlined, from breast cancer “average” through “very high” risk, the latter including individuals with high penetrance BRCA1/2 gene mutations, and guidelines for management of patients in each of these categories were discussed.
Journal ArticleDOI
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.
Erica L. Carpenter,Rosemarie Mick,Andrew J. Rech,Gregory L. Beatty,Theresa A. Colligon,Myrna R. Rosenfeld,David E. Kaplan,Kyong-Mi Chang,Susan M. Domchek,Peter A. Kanetsky,Leslie A. Fecher,Keith T. Flaherty,Lynn M. Schuchter,Robert H. Vonderheide +13 more
TL;DR: Disturbed B-cell homeostasis is a previously unrecognized feature of patients with advanced melanoma and other cancers and may represent an unanticipated mechanism of immune incompetence in cancer.
Journal ArticleDOI
Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.
Gwenn-ael Danet-Desnoyers,Jennifer L. Luongo,Dominique Bonnet,Susan M. Domchek,Robert H. Vonderheide +4 more
TL;DR: It is suggested that induction of tumor-lytic hTERT-specific T cells in vivo by vaccination does not result in a detectable decline in hematopoietic potential despite the expression of h TERT and major histocompatibility complex class I in bone marrow progenitors and stem cells.
Journal ArticleDOI
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne C Armstrong,W. Wu,C. Goessl,Sarah Runswick,Pierfranco Conte +13 more
TL;DR: OlympiAD was a randomized, open-label, phase III study that assessed efficacy and safety of olaparib vs standard single agent chemotherapy treatment of physician’s choice (TPC) in pts with HER2-negative mBC and a gBRCAm.
Journal ArticleDOI
814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Yvette Drew,Richard T. Penson,David M. O'Malley,J-W. Kim,Stefan Zimmermann,Patricia Roxburgh,Joohyuk Sohn,Salomon M. Stemmer,S Bastian,M. Ferguson,Benoit You,Susan M. Domchek,H. Gao,Helen K. Angell,K. Meyer,L Opincar,L. Ottesen,D.O. Koralek,Susana Banerjee +18 more